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By combining genome-wide association data from 8,130 individuals with type 2 diabetes (T2D)
and 38,987 controls of European descent and following up previously unidentified meta-analysis
signals in a further 34,412 cases and 59,925 controls, we identified 12 new T2D association
signals with combinedP < 5 × 10−8. These include a second independent signal at the KCNQ1
locus; the first report, to our knowledge, of an X-chromosomal association (near DUSP9); and a
further instance of overlap between loci implicated in monogenic and multifactorial forms of
diabetes (at HNF1A). The identified loci affect both beta-cell function and insulin action, and,
overall, T2D association signals show evidence of enrichment for genes involved in cell cycle
regulation. We also show that a high proportion of T2D susceptibility loci harbor independent
association signals influencing apparently unrelated complex traits.
Type 2 diabetes (T2D) is characterized by insulin resistance and deficient beta-cell
function1. The escalating prevalence of T2D and the limitations of currently available
preventative and therapeutic options highlight the need for a more complete understanding
of T2D pathogenesis. To date, approximately 25 genome-wide significant common variant
associations with T2D have been described, mostly through genome-wide association
(GWA) analyses2-13. The identities of the variants and genes mediating the susceptibility
effects at most of these signals have yet to be established, and the known variants account
for less than 10% of the overall estimated genetic contribution to T2D predisposition.
Although some of the unexplained heritability will reflect variants poorly captured by
existing GWA platforms, we reasoned that an expanded meta-analysis of existing GWA data
would offer augmented power to detect additional common variant signals of modest effect.
RESULTS
GWA meta-analysis and replication
We conducted a meta-analysis of eight T2D GWA studies comprising 8,130 T2D cases and
38,987 controls of European descent. We combined case-control data from the Wellcome
Trust Case Control Consortium (WTCCC), Diabetes Genetics Initiative (DGI) and Finland-
US Investigation of NIDDM genetics (FUSION) scans (the subjects of a previous joint
analysis7), with those from scans performed by deCODE genetics6, the Diabetes Gene
Discovery Group2, the Cooperative Health Research in the Region of Augsburg group
(KORAgen), the Rotterdam study and the European Special Population Research Network
(EUROSPAN). The effective sample size (n = 22,044) of stage 1 of the current (hereafter
designated ‘DIAGRAM+’) meta-analysis was more than twice that of the earlier
DIAGRAM (DIAbetes Genetics Replication and Meta-analysis) study7. After genomic
control correction of each component study, we combined association data for 2,426,886
imputed and genotyped autosomal SNPs into a fixed-effects, additive-model meta-analysis
using the inverse-variance method (Online Methods, Fig. 1, Supplementary Tables 1 and 2
and Supplementary Note). We observed only modest genomic control inflation (λgc = 1.07),
suggesting that the observed results were not due to population stratification. After removing
SNPs within established T2D loci (Supplementary Table 3), the resulting quantile-quantile
plot was consistent with a modest excess of disease associations of relatively small effect
(Supplementary Note). Weak evidence for association at HLA variants strongly associated
with autoimmune forms of diabetes (Supplementary Table 3 and Supplementary Note)
suggested some case admixture involving subjects with type 1 diabetes or latent
autoimmune diabetes of adult-hood; however, failure to detect T2D associations at other
non-HLA type 1 diabetes susceptibility loci (for example, INS, PTPN22 and IL2RA)
indicated that any such misclassification was too modest to drive stage 1 associations
outside the HLA. The stage 1 meta-analysis also provided further confirmation of many
previously reported signals and, at some of these, refinement of the peak association signal
(Fig. 1, Supplementary Table 3 and Supplementary Note).
Voight et al. Page 4
Nat Genet. Author manuscript; available in PMC 2011 April 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
We selected for stage 2 follow-up the most strongly associated SNP from each of the 23 new
autosomal regions showing the most compelling evidence for association (all P < 10−5 in
stage 1; Supplementary Table 3). We combined exclusively in silico data from three GWA
samples (Atherosclerosis Risk in Communities (ARIC) study, Nurses’ Health Study and
Framingham Heart Study) not included in the primary meta-analysis (2,832 cases and
15,843 controls) with additional (predominantly de novo) genotyping in up to 31,580 cases
and 44,082 controls, for a maximum possible stage 2 sample size of 34,412 cases and 59,925
controls (effective sample size of 79,246), all of European descent (Supplementary Tables
1 and 2).
Stage 2 analyses indicated that the set of 23 signals was enriched for true association signals.
In all, 21 showed directional consistency of effect between stage 1 and 2 (binomial test, P
~3.3 × 10−5), and for 15, the stage 2 P value was <0.05 (Supplementary Note). In joint
analysis of stage 1 and 2 data (up to 42,542 cases and 98,912 controls), 13 autosomal loci
exceeded the threshold for genome-wide significance (P ranging from 2.8 × 10−8 to 1.4 ×
10−22) with allele-specific odds ratios (ORs) between 1.06 and 1.14 (Table 1 and Fig. 2). All
signals remained close to or beyond genome-wide significance thresholds (the least
significant P value was 5.2 × 10−8) when we repeated analyses after implementing a second
(post meta-analysis) round of genomic control adjustment within stage 1 data
(Supplementary Note).
We extended our search for susceptibility signals to the X chromosome, identifying one
further signal in the stage 1 discovery samples meeting our criteria for follow-up
(represented by rs5945326, near DUSP9, P = 2.3 × 10−6). This SNP showed strong evidence
for replication in 8,535 cases and 12,326 controls (OR (allowing for X-inactivation) 1.32
(95% CI 1.16–1.49), P = 2.3 × 10−5), for a combined association P value of 3.0 × 10−10 (OR
1.27 (95% CI 1.18–1.37)) (Table 1 and Fig. 2).
Fourteen signals reaching genome-wide significance
Two of the 14 signals reaching genome-wide significance on joint analysis (those near
MTNR1B and IRS1) represent loci for which T2D associations have been recently reported
in samples which partially overlap with those studied here10,14-16 (Table 1).
A third signal (rs231362) on 11p15 overlaps both intron 11 of KCNQ1 and the KCNQ1OT1
transcript that controls regional imprinting17 and influences expression of nearby genes
including CDKN1C, a known regulator of beta-cell development18. This signal maps ~150
kb from T2D-associated SNPs in the 3′ end of KCNQ1 first identified in East Asian GWA
scans8,9. SNPs within the 3′ signal were also detected in the current DIAGRAM+ meta-
analysis (for example, rs163184, P = 6.8 × 10−5), but they failed to meet the threshold for
initiating replication. A SNP in the 3′ region (rs2237895) that was reported to reach
genome-wide significance in Danish samples9 was neither typed nor imputed in the
DIAGRAM+ studies. In our European-descent samples, rs231362 and SNPs in the 3′ signal
were not correlated (r2 < 0.05), and conditional analyses (see below) establish these SNPs as
independent (Fig. 2 and Supplementary Table 4). Further analysis in Icelandic samples has
shown that both associations are restricted to the maternally transmitted allele11. Both T2D
loci are independent of the common variant associations with electrocardiographic QT
intervals that map at the 5′ end of KCNQ1 (r2 < 0.02, D′ < 0.35 in HapMap European CEU
data)19,20 (Supplementary Table 5).
Of the remaining loci, two (near BCL11A and HNF1A) have been highlighted in previous
studies7,21-23 but are now shown to reach genome-wide significance. Rare mutations in
HNF1A account for a substantial proportion of cases of maturity onset diabetes of the
young, and a population-specific variant (G319S) influences T2D risk in Oji-Cree Indians24.
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Confirmation of a common variant association at HNF1A brings to five the number of loci
known to harbor both rare mutations causal for monogenic forms of diabetes and common
variants predisposing to multifactorial diabetes, the others being PPARG, KCNJ11, WFS1
and HNF1B. A T2D association in the BCL11A region was suggested by the earlier
DIAGRAM meta-analysis (rs10490072, P = 3 × 10−5), but replication was inconclusive7;
there is only modest linkage disequilibrium (LD) between rs10490072 and the lead SNP
from the present analysis (rs243021, r2 = 0.22, D′ = 0.73 in HapMap CEU).
The remaining nine signals map near the genes HMGA2, CENTD2, KLF14, PRC1,
TP53INP1, ZBED3, ZFAND6, CHCHD9 and DUSP9 (Table 1 and Figs. 1 and 2) and
represent new T2D risk loci uncovered by the DIAGRAM+ meta-analysis.
Understanding the genetic architecture of type 2 diabetes
Combining newly identified and previously reported loci and assuming a multiplicative
model, the sibling relative risk attributable to the 32 T2D susceptibility variants described in
this paper is ~1.14. With addition of the five T2D loci recently identified by the Meta-
Analysis of Glucose and Insulin-related traits Consortium (MAGIC) investigators12,13 and
incorporation of estimates of parent-of-origin–specific effect sizes observed at the KCNQ1
and KLF14 signals and at a recently described locus on chromosome 11p15 (which confers
substantial risk when paternally inherited but is protective when maternally transmitted11),
this figure rises to ~1.16. Given estimates of sibling relative risk for T2D in Europeans of ~3
(ref. 25), variant discovery efforts to date have therefore explained only ~10% of observed
familial clustering. We used available data to evaluate several mechanisms that might be
contributing to that proportion of familiality which reflects residual, unexplained
heritability26.
Copy number variants (CNVs)—We re-examined stage 1 data looking for associations
with SNPs known to provide robust, high-LD tags for common CNVs in European
populations. After combining four inventories of CNV-tagging SNPs that survey at least
40% of common CNVs genome-wide >1 kb in size, we found no convincing evidence that
this class of variants contributes substantially to T2D risk (Supplementary Note).
Secondary signals revealed by conditional analysis—If there are additional
independent susceptibility variants at the loci identified, total genetic variance attributable to
these regions will be underestimated when based on the lead common variants alone. To
explore the potential for independent secondary alleles, we repeated the stage 1 meta-
analysis after simultaneously conditioning on 30 known and newly discovered autosomal
loci (Supplementary Note). Using a cutoff of P < 1 × 10−4 (to reflect approximate
adjustment for the number of independent SNPs in a ~2 Mb interval), we found preliminary
evidence for secondary signals at five loci (TP53INP1, CDKN2A, HHEX-IDE and
KCNJ11, in addition to that at KCNQ1; Fig. 1, Supplementary Fig. 1 and Supplementary
Table 4). At CDKN2A, the secondary signal is consistent with evidence that haplotype-
based analyses generate considerably stronger evidence for association than either signal
alone3,27. Further fine-mapping efforts will be required to confirm the secondary signals at
TP53INP1, HHEX-IDE and KCNJ11.
The conditional analysis also provided preliminary (P < 10−5, our stage 1 threshold)
evidence for 19 signals outside known loci (Fig. 1 and Supplementary Table 6). The most
notable signal (rs1481279, conditional P = 8.4 × 10−9) maps near NHEDC1 and corresponds
to one of the signals of interest following stage 1 (rs7674212, P = 1.7 × 10−7 unconditioned).
Failure to replicate that signal (P = 0.3 in 21,889 stage 2 cases and 39,568 controls) suggests
this was a false positive (Supplementary Note). Several regions showed substantial
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incremental evidence for association in the conditional analysis as compared to unadjusted
analyses and represent potential targets for large-scale replication and gene-gene interaction
analyses. Indeed, one of these regions (at rs11708067 near ADCY5, unadjusted P = 1.7 ×
10−4, conditional P = 2.2 × 10−6) has recently been shown, following initial identification
through GWA analysis of continuous glucose measures, to have genome-wide significant
associations with T2D in large-scale case-control analyses that involved several DIAGRAM
+ samples12,13.
Etiological heterogeneity—To determine whether etiological heterogeneity might have
compromised power to detect genuine T2D susceptibility signals, we performed BMI- and
age-of-diagnosis (AOD)-stratified analyses within stage 1 data. We compared effect size
estimates for all known T2D risk variants in 2,877 obese (defined as BMI > 30 kgm−2) and
4,048 nonobese (BMI ≤ 30 kgm−2) T2D cases when compared to similarly stratified controls
(Supplementary Note). Although risk estimates for 23 of the 30 autosomal loci were
numerically greater in the nonobese comparison than in the obese comparison (binomial test,
P = 0.0018), only TCF7L2 (P < 0.001) and BCL11A (P = 0.02) showed significant (P <
0.05) evidence for effect-size heterogeneity. For AOD, we compared risk-locus genotypes
for 1,317 cases with AOD <45 years of age and 4,283 cases with AOD >45 years of age, as
well as continuous analyses of AOD within all cases (n = 7,104; Supplementary Note), and
found no strong evidence of differential effects. Although recognizing that BMI at
examination and AOD are imperfect measures of BMI and age at disease onset, we conclude
that a focus on more homogeneous subsamples would not have provided more efficient
identification of known T2D susceptibility variants. Furthermore, these data argue against
the potential for these common variant signals to afford clinically useful subclassification of
individuals with T2D.
Overlap with GWA signals for other diseases—We noted that seven of the newly
discovered autosomal loci (near BCL11A, ZBED3, KLF14, CHCHD9, HMGA2, HNF1A
and PRC1) are characterized by strong (P < 10−6) associations with phenotypes other than
T2D (Supplementary Table 5). In each case, these appear to be distinct and independent
signals. For example, variants at the 3′ end of HMGA2 (~180 kb distant from the T2D
signal) have widely replicated effects on adult height28 but are weakly correlated with the
T2D-associated SNP rs1531343 (r2 < 0.01, D′ < 0.15 in HapMap CEU). The KLF14 region
harbors distinct signals for both T2D and basal cell carcinoma29. At HNF1A, previous
studies have reported a cluster of associations, with phenotypes including low-density
lipoptrotein (LDL) cholesterol30 and circulating C-reactive protein levels31-33, mapping
~18–72 kb from the peak T2D signal. Though these two sets of HNF1A signals maintain
appreciable LD in European samples (r2 ~0.1, D′ ~1), they are likely to be independent; the
T2D association at the lead SNP for lipids (rs2650000) is far weaker than the association at
rs7957197 (P = 0.003 compared to P = 4.6 × 10−7 in stage 1 samples), whereas LDL
cholesterol shows a reciprocal pattern of association (P = 7 × 10−9 at rs2650000 compared to
P = 0.73 at rs7957197 in the same lipid meta-analysis data30).
If we include the KCNQ1 associations described above, previous reports at JAZF1,
CDKN2A and CDKAL1 (refs. 34-40) and other signals identified by systematic analysis of
the National Human Genome Research Institute (NHGRI) GWA catalog41 (Supplementary
Table 5 and Supplementary Note), at least 13 of 30 autosomal T2D loci show this pattern of
closely approximated (within 500 kb) but distinct associations with traits other than T2D or
related anthropometric and glycemic phenotypes. This is in addition to what appear to be
coincident signals involving T2D susceptibility variants at IRS1 (associated with coronary
disease), JAZF1 (associated with height) and HNF1B (associated with prostate cancer)
(Supplementary Table 5). Simulations conducted using the NHGRI catalog as a reference set
indicate that the number of non-T2D signals observed at T2D loci significantly exceeds
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expectation (P ~1.6 × 10−3 for non-T2D signals within 500 kb of T2D loci, P ~7.0 × 10−5 (n
= 8) for non-T2D signals within 100 kb of T2D loci). Many of these instances of
colocalization may represent variants within different regulatory domains that result in
tissue- and disease-specific effects mediated through the same genes and pathways.
Understanding the biology of T2D-susceptibility loci
This analysis takes the number of independent loci showing genome-wide significant
associations with T2D beyond 35. For some, such as those at KCNJ11 and SLC30A8, the
molecular mechanisms responsible for the susceptibility effect can be assigned with some
confidence42. At others, the identities of the causal variants, the genes through which they
act and the pathophysiological processes which they influence remain obscure. We used
several approaches designed to link DIAGRAM+ and previously reported T2D association
signals to biological insights relevant to T2D pathogenesis.
Physiological analyses—Variants at FTO are known to influence T2D predisposition
through an effect on BMI. In ~21,000 population sample individuals from the GWA meta-
analysis of adult BMI completed by the Genetic Investigation of ANthropmetric Traits
(GIANT) consortium43, no other autosomal T2D susceptibility locus had the property that
the T2D risk allele was significantly associated with higher BMI (Supplementary Note).
FTO is therefore the only one of the known T2D signals driven by a strong primary causal
association with obesity.
We also examined the effect of T2D susceptibility alleles on continuous glycemic measures
in up to 46,186 nondiabetic subjects from the MAGIC meta-analysis12,13. Coefficients for
association between the T2D risk allele and higher fasting glucose were positive for 28 of
the 31 loci, and 17 of these T2D loci showed significant (P < 0.05) directionally consistent
associations with fasting glucose (Fig. 3 and Supplementary Note). However, the
magnitudes of effect sizes for fasting glucose and T2D were only weakly correlated
(Supplementary Fig. 2 and Supplementary Note), indicating that the mechanisms
influencing normal glucose homeostasis and those responsible for the development of T2D
are not entirely congruent. T2D risk alleles at four loci (at PPARG, FTO, IRS1 and KLF14)
were associated (P < 0.05) with higher fasting insulin, consistent with a primary effect on
insulin action, whereas at three other loci (at TCF7L2, CENTD2 and CDKAL1), the
association with reduced fasting insulin indicates beta-cell dysfunction (Fig. 3). Indices of
beta-cell function (HOMA-B) and insulin sensitivity (HOMA-IR) derived from paired
fasting glucose and insulin measures from ~37,000 individuals supported these mechanistic
inferences (Fig. 3). In all, risk alleles at ten loci (the previously reported loci at MTNR1B,
SLC30A8, THADA, TCF7L2, KCNQ1, CAMK1D, CDKAL1, IGF2BP2 and HNF1B and
the newly discovered locus at CENTD2) were associated (P < 0.05) with reduced beta-cell
function, and three loci (previously reported loci at PPARG and FTO and the newly
discovered locus at KLF14) were associated with reduced insulin sensitivity. The
associations with improved insulin sensitivity evident for risk alleles at TCF7L2, IGF2BP2
and CDKAL1 probably reflect truncated ascertainment, as the MAGIC analyses were
restricted to nondiabetic individuals. For the previously reported loci, these findings are
broadly consistent with those from more detailed physiological studies6,8,44 and suggest
that, of the newly discovered loci, the risk alleles at CENTD2 modify T2D susceptibility
through a detrimental effect on beta-cell function. In contrast, the risk alleles at KLF14 and
possibly HMGA2 (ref. 45), along with those at PPARG, IRS1 (ref. 10) and ADAMTS9 (ref.
46), appear to have a primary effect on insulin action which is not driven by obesity, unlike
the alleles at FTO. The MAGIC meta-analysis did not extend to the X chromosome, but
analysis of rs5945326, near DUSP9, in a sub-set of MAGIC samples (n = 14,644–21,118),
revealed no significant (P < 0.05) associations with any fasting glycemic trait. For this
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signal, as with the other newly identified loci, more detailed phenotypic analyses will be
required to determine how these impact T2D risk. Overall, these data are consistent with the
impression that common T2D risk alleles more often act through beta-cell dysfunction12,44,
but they provide further examples of T2D risk variants that exert their primary effects on
insulin action.
Expression analyses—We used expression data to seek clues to the genes mediating the
T2D susceptibility effects we had detected. First, we examined expression-QTL (eQTL) data
(in 23,720 transcripts) for subcutaneous adipose tissue (n = 603 with GWA data) and blood
(n = 745) samples typed with the Illumina 300K chip47 (Table 2 and Supplementary Note).
Among the newly identified loci, the most compelling signal was at rs972283, strongly
associated with expression of KLF14 in adipose tissue and correlated (r2 = 0.3 in HapMap
CEU) with the SNP (rs738134) with the strongest KLF14 cis expression signal. Both the
T2D and cis eQTL associations at this locus showed strong parent-of-origin effects11. At the
TP53INP1 locus, the cis-eQTL data suggest the T2D susceptibility effect is mediated via
altered CCNE2 expression. In contrast, the significant cis-eQTL associations at the ZBED3,
CENTD2, HNF1A and PRC1 T2D susceptibility signals are likely to be misleading, as the
patterns of conditional association indicate that the T2D association and cis eQTL signals
are not coincident. At previously reported T2D association signals, we found strong overlap
with cis eQTL effects for IRS1 (consistent with data on IRS1 protein expression and
function in skeletal muscle10), JAZF1 and CAMK1D7.
We also explored the tissue expression profiles of 27 autosomal genes mapping to the newly
discovered regions of association and performed quantitative RT-PCR analyses across a
panel of human tissues relevant to T2D pathogenesis (Supplementary Note). The broad
expression of many of the transcripts, including 24 transcripts with evidence of beta-cell
transcription (Supplementary Note), limited our ability to prioritize among candidate
transcripts on the basis of static patterns of transcript expression.
Pathway and protein-protein interaction analyses—Reasoning that the additional
T2D susceptibility loci would amplify our ability to identify over-represented molecular
processes48, we deployed several complementary approaches to detect evidence of pathway
or network enrichment (Supplementary Note). Using GRAIL49, we found that genes within
T2D-associated regions showed evidence of increased connectivity within PubMed
abstracts, though this largely reflects shared roles in monogenic or syndromic diabetes
(involving HNF1A, HNF1B and WFS1). We also showed that the extent of protein-protein
interaction between the products of genes mapping to the association signals substantially
exceeded expectation (Supplementary Note). Pathway enrichment analyses using the
PANTHER database50 uncovered some evidence of over-representation of signal
transduction and protein metabolism and modification, and Reactome51 highlighted a
separate set of pathways including metabolism of lipids and lipoproteins, endothelins and
beta-arrestins (for details, see Supplementary Note).
The only consistent signal to emerge across multiple analyses involved cell-cycle regulation.
Network analyses based on protein-protein interaction data detected (unadjusted P ~0.004)
an 18-member subnetwork characterized by enhanced protein-protein interaction
connectivity and highly enriched for genes implicated in cell cycle regulation (P = 2.8 ×
10−7). A smaller (five, only partly overlapping genes) cell-cycle network independently
emerged from the Reactome analyses, and gene-set enrichment analysis of selected
candidate pathways52 also detected over-representation of association signals (P ~0.006)
among cell-cycle genes (Supplementary Note). Because many genes within these networks
are expressed in pancreatic islets and T2D-association effects at several of these loci are
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mediated primarily through beta-cell dysfunction44, these findings highlight the contribution
of regulation of beta-cell mass to the long-term maintenance of normal glucose homeostasis.
In addition, these analyses highlighted notable biological connections between sets of genes
within confirmed T2D-association regions. For example, HMGA2 emerges as a key
transcriptional regulator of IGF2BP2 (refs. 53,54). However, because Hmga/Hmg1c
knockout mice are deficient in adipocyte differentiation45, and the IGF2BP2 risk allele is
associated with reduced beta-cell function55, further work is required to establish the
relevance of this regulatory interaction to T2D pathogenesis. Our analyses also revealed that
TLE4 (at the CHCHD9 locus) encodes a homolog of Groucho that forms complexes with
TCF proteins, including TCF7L2, to modulate transcription at target sites56. Finally,
FURIN, one of the genes mapping to the newly identified PRC1 locus, encodes a paired
basic amino acid cleaving enzyme; both NOTCH2 and ADAMTS9 (ref. 7) are known targets
of FURIN cleavage57-59.
Notably, these global approaches failed to provide any consistent support for many other
mechanisms previously promoted on the basis of biochemical or physiological evidence as
likely contributors to T2D pathogenesis1 (Supplementary Note). Overall, the relative paucity
of signals from these analyses—particularly when contrasted with the compelling patterns of
enrichment seen for other complex traits48—indicates, either that T2D pathogenesis is
characterized by substantial etiological heterogeneity or that the processes critical to T2D
development are poorly represented in existing pathway and interaction databases.
DISCUSSION
By increasing the discovery sample size, our study has substantially expanded the number of
loci for which there is strong statistical evidence indicating a role in T2D predisposition.
When combined with recent reports of additional T2D susceptibility loci arising from
studies of continuous glycemic traits12,13 and parent-of-origin effects11, the number of
confirmed loci for T2D currently stands at 38.
Although these discoveries represent new opportunities to explore the biology of T2D
predisposition, the challenges inherent in translating these common variant association
signals into biological mechanisms of disease causation are clear. Nevertheless, the analyses
we report have generated several mechanistic hypotheses that can direct future efforts at
functional evaluation and genetic refinement. At some loci, particularly those near HNF1A,
HMGA2 and KLF14, existing biology, coupled with phenotypic and expression data
presented here, highlight the named genes as prime candidates for mediating the
susceptibility effect. For example, the T2D susceptibility effect near KLF14, which maps
within an imprinted region on chromosome 7q32 and which, on the basis of the MAGIC
meta-analysis data, appears to be driven by reduced insulin action, is restricted to the
maternally transmitted allele11. As KLF14 is maternally expressed, and the eQTL
association between rs972283 and KLF14 expression (see above) is similarly restricted to
the maternal allele, KLF14 (a widely expressed, intronless member of the Krüppel-like
family of transcription factors60) emerges as the main regional candidate. At the X-
chromosome signal, evidence implicating DUSP9 (mitogen-activated protein kinase
phosphatase-4) in the regulation of insulin action in mice gives DUSP9 particular salience as
an association candidate61,62. However, as described above, failure to detect associations
with continuous glycemic phenotypes (including fasting insulin and HOMA-IR) means that
the functional connection with DUSP9 remains speculative.
In other regions, such as those near PRC1, TP53INP1 and CHCHD9, the functional
connections and/or eQTL associations of particular genes mapping within or close to the
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respective association intervals show FURIN, CCNE2 and TLE4, respectively, to be
promising biological candidates. At yet other loci, such as those centered around ZBED3,
CENTD2 and ZFAND6, existing data provide little, if any, basis for strong inferences
concerning the genes likely to mediate the T2D susceptibility effect. Accumulation of new
data—through deep resequencing of the regions, fine-mapping and functional studies in
humans and in animal models—will be required to characterize the specific variants
responsible and the genes and pathways through which they execute their effect on T2D
risk.
One theme emerging from this work is the high frequency with which loci implicated in
T2D susceptibility harbor variants that influence other common traits. This colocalization of
common risk variants exceeds chance expectation, often connects diseases with little
obvious mechanistic overlap and typically involves statistically independent susceptibility
signals. Recent evidence that tissue-specific eQTL signals are preferentially located in
regulatory sequences some distance from transcriptional start sites63—in common with
many complex trait association signals—suggests that further dissection of these regions
should improve understanding of the genomic organization of tissue- and/or developmental-
stage-specific regulation.
A further conclusion is that common SNP signals are likely to fall short in explaining the
observed familial aggregation of T2D, at least in European descent populations. The limited
power of our study (Table 1) to detect several of the genome-wide significant variants we
report here (based on the stage 1 sample size and stage 2 odds ratios that minimize ‘winner’s
curse’ effects) indicates that there are likely to be many additional common variant signals
of similar effect that could be detected by further expansion of the GWA meta-analysis
approach. However, it seems unlikely that these will explain a substantial proportion of
unex-plained heritability. Based on the data presented, the same is likely to be true for
common CNVs and for variation on the sex chromosomes. As a result, the attention of
researchers in the field is increasingly directed toward evaluation of the contribution of low
frequency and rare variants to complex trait susceptibility. Several lines of evidence—the
overlap in loci implicated in monogenic and multifactorial diabetes, the congregation of
multiple disease signals at a limited number of loci the conditional analyses—point toward
the importance of obtaining complete descriptions of causal genetic variation (of all types
and frequencies) at the loci uncovered by this and other GWA studies. Such loci are likely to
represent hotspots at which the overall contribution to T2D predisposition and biology may
be considerably greater than that estimated using the discovered common variants alone.
METHODS
Methods and any associated references are available in the online version of the paper at
http://www.nature.com/naturegenetics/.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Genome-wide Manhattan plots for the DIAGRAM+ stage 1 meta-analysis. Top panel
summarizes the results of the unconditional meta-analysis. Previously established loci are
denoted in red and loci identified by the current study are denoted in green. The ten signals
in blue are those taken forward but not confirmed in stage 2 analyses. The genes used to
name signals have been chosen on the basis of proximity to the index SNP and should not be
presumed to indicate causality. The lower panel summarizes the results of equivalent meta-
analysis after conditioning on 30 previously established and newly identified autosomal
T2D-associated SNPs (denoted by the dotted lines below these loci in the upper panel).
Newly discovered conditional signals (outside established loci) are denoted with an orange
dot if they show suggestive levels of significance (P < 10−5), whereas secondary signals
close to already confirmed T2D loci are shown in purple (P < 10−4).
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Figure 2.
Regional plots of the 12 newly discovered T2D loci. Genotyped and imputed SNPs passing
quality control measures across all stage 1 studies are plotted with their meta-analysis P
values (as −log10 values) as a function of genomic position (NCBI Build 36). In each panel,
the index association SNP is represented by a diamond, with stage 1 meta-analysis results
denoted by a red diamond and the combined stage 1 and stage 2 meta-analysis results
denoted with a clear symbol. Estimated recombination rates (taken from HapMap CEU) are
plotted to reflect the local LD structure. Color of remaining SNPs (circles) indicates LD with
the index SNP according to a scale from r2 = 0 to r2 = 1 based on pairwise r2 values from
HapMap CEU (red, r2 = 0.8–1.0; orange, r2 = 0.6–0.8; green, r2 = 0.4–0.6; blue, r2 = 0.2–
0.4; black, r2 < 0.2; gray, no r2 value available). Gene annotations were taken from the
University of California Santa Cruz genome browser.
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Figure 3.
Plots of fasting blood glucose, insulin and derived indices for the established and new T2D
loci. (a,b) Plots of fasting glucose (x axis) and fasting insulin (y axis). (c,d) Plots of HOMA-
B (an index of beta cell function; x axis) and HOMA-IR (an index of insulin sensitivity; y
axis). Each point refers to a single T2D association signal, with colors denoting the strength
of the association to either the x-axis variable (left-hand of each pair of plots) or y-axis
variable (right-hand of each pair) (red, P < 10−3; orange, 10−3 < P < 10−2; yellow, 0.01 < P <
0.05; green, 0.05 < P < 0.20; blue, P > 0.20). The two KCNQ1 associations are distinguished
by the notation KCNQ1 for rs163184 and KCNQ1* for rs231362. The gene names
associated with each signal have been chosen on the basis of proximity to the index SNP and
should not be presumed to indicate causality.
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